Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Aug 1.

Published in final edited form as: J Alzheimers Dis. 2012;29(3):691–697. doi: 10.3233/JAD-2012-110629

Fig. 2 — Percent composition of docosahexaenoic acid in brain phos-phatidylserine (% DHA-PS) in three brain regions in persons with no cognitive impairment. Bars are for no cognitive impairment (■, n = 12), mild cognitive impairment ( , n = 12), or Alzheimer’s disease (□, n = 12). Data for Alzheimer’s disease were significantly different from both no cognitive impairment and mild cognitive impairment groups in the midfrontal cortex (**p = 0.014; Kruskal-Wallis followed by Mann Whitney tests) and in the superior temporal cortex (*p = 0.03; Kruskal-Wallis test). No other differences in fatty acid composition for these brain regions were observed across the three groups, or across the four brain phospholipid classes studied, regardless of whether the data were expressed as concentration (mg/g) or % composition.

Inline graphic — Percent composition of docosahexaenoic acid in brain phos-phatidylserine (% DHA-PS) in three brain regions in persons with no cognitive impairment. Bars are for no cognitive impairment (■, n = 12), mild cognitive impairment ( , n = 12), or Alzheimer’s disease (□, n = 12). Data for Alzheimer’s disease were significantly different from both no cognitive impairment and mild cognitive impairment groups in the midfrontal cortex (**p = 0.014; Kruskal-Wallis followed by Mann Whitney tests) and in the superior temporal cortex (*p = 0.03; Kruskal-Wallis test). No other differences in fatty acid composition for these brain regions were observed across the three groups, or across the four brain phospholipid classes studied, regardless of whether the data were expressed as concentration (mg/g) or % composition.